Try our Advanced Search for more refined results
Life Sciences
-
January 08, 2026
ITC To Investigate Smartwatch Giants Over Fall Detection IP
The U.S. International Trade Commission on Thursday said it will review whether Apple, Google, Garmin and Samsung are infringing UnaliWear Inc.'s patents with their smartwatch imports.
-
January 08, 2026
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition
Eli Lilly and Co. has agreed to acquire Ventyx Biosciences Inc., a San Diego-based clinical-stage biopharmaceutical company, for about $1.2 billion in cash, with Ropes & Gray LLP and Wilson Sonsini Goodrich & Rosati PC advising.
-
January 08, 2026
Cooley Adds Longtime Sidley Healthcare Attorney In DC
A longtime Sidley Austin LLP attorney has moved to Cooley LLP's global life sciences and healthcare regulatory practice in Washington, D.C.
-
January 08, 2026
Leason Ellis Hires 9 Life Sciences Pros From Haley Guiliano
Leason Ellis LLP announced Thursday that it has hired nine professionals with backgrounds in the life sciences from Haley Guiliano LLP, a patent practice that originated as a spin-off from Ropes & Gray LLP.
-
January 08, 2026
Cooley-Led Eir Partners Wraps $1B Health Tech Fund
Cooley LLP-advised private equity shop Eir Partners Capital LP on Thursday announced that it wrapped its third fund with $1 billion of investor commitments, which will be used to invest in health technology and technology-enabled services businesses.
-
January 08, 2026
Trump Admin Can't Undo Block On Drug Rebate Program
A First Circuit panel has refused to lift a district judge's block on a Trump administration plan to pilot a rebate model for a federal drug discount program that benefits low-income patients, saying the federal government is unlikely to win its appeal.
-
January 08, 2026
Husch Blackwell Expands With 18-Person Immigration Team
Husch Blackwell LLP has hired an 18-person immigration team made up of two lawyers, eight paralegals and eight business professionals from an Illinois boutique, the firm announced this week.
-
January 07, 2026
Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal
A biotech company that developed a patented protein technology that allegedly expedited the development of Moderna's COVID-19 Spikevax vaccine sued the U.S. Department of Health and Human Services on Wednesday, claiming the feds infringed its patent through a contract to develop a vaccine with the pharma giant.
-
January 07, 2026
Amazon Seeks To Halt Supplement Suit As FDA Nixes Rule
Amazon called on a Seattle federal judge to pause a proposed class action accusing the e-commerce platform of failing to make certain disclosures on supplement product pages, saying the U.S. Food and Drug Administration plans to revoke the so-called each panel labeling rule at the center of the case.
-
January 07, 2026
Fed. Circ. Suggests Sepsis Test IP Needs Claim Construction
U.S. Circuit Judge Todd M. Hughes appeared largely persuaded Wednesday that a Delaware federal jury improperly engaged in post-trial claim construction when overriding Magnolia Medical Technologies Inc.'s $2 million infringement verdict, in an appeal that also had the Federal Circuit jurist thanking God that he doesn't try patent cases.
-
January 07, 2026
Potomac Law Adds Former DOJ, HHS Civil Rights Atty
Potomac Law Group has hired a healthcare attorney with over 15 years working on LGBTQ+ protections and other civil rights issues at the Justice Department and the Department of Health and Human Services.
-
January 07, 2026
Kaplan Fox Remains Lead In Securities Suit After Ex-Client DQ
Kaplan Fox & Kilsheimer LLP will continue leading a putative securities class action against Spectrum Pharmaceuticals after a previously appointed lead plaintiff was removed from the case for allegedly going behind his lawyers' backs to push his own settlement plan and unrelated conspiracy theories.
-
January 07, 2026
Detroit Pension Fund Wins 'Close' Call To Lead Investor Suit
A Detroit pension fund should lead a proposed shareholder class action against MoonLake Immunotherapeutics, though a competing bid by a France-based lab worker and screenwriter alleges a "marginally larger" investment loss, a Manhattan federal judge has determined.
-
January 06, 2026
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties
Bayer wants a cut of the profits Johnson & Johnson, Moderna, Pfizer and BioNTech have reaped from sales of their COVID-19 vaccines, which the German biotech company alleges were only made possible through infringement of its intellectual property, according to lawsuits filed Tuesday in New Jersey and Delaware federal courts.
-
January 06, 2026
Cigna Accused Of Rigging Market For Life-Saving Drugs
Patients with chronic health conditions sued Cigna in an Illinois federal court alleging in a proposed class action Tuesday that the company and its pharmacy and pharmacy benefit manager subsidiaries use exclusive agreements to lock users into a network where Byzantine refill processes have been deliberately erected to limit payouts for life-saving drugs.
-
January 06, 2026
FDA To Ease Regulation Of Wearables, Decision Software
U.S. Food and Drug Administration Commissioner Marty Makary touted new federal guidance on Tuesday that he said would promote innovation by making it easier to bring certain kinds of wearable devices and clinical-decision software to market without a strict regulatory review.
-
January 06, 2026
1st Circ. Questions Feds' Mootness Claim In NIH Grant Suits
The First Circuit appeared to push back Tuesday on assertions by the government that new guidance for terminating medical research grants over supposed links to issues like DEI, gender identity and vaccines — along with a partial settlement last week — moot a pair of lawsuits challenging the directives.
-
January 06, 2026
RFK Jr. Can't Avoid Medical Groups' Challenge To Vax Policy
A Boston federal judge on Tuesday rebuffed U.S. Health and Human Services Secretary Robert F. Kennedy Jr.'s bid to dismiss a challenge to vaccine policy changes, saying medical associations have plausibly alleged a federal vaccine committee is not fairly balanced.
-
January 06, 2026
NJ Judge Signals Green Light To Revive J&J Unit's Libel Suit
A New Jersey federal judge has indicated she is planning to grant a bankrupt Johnson & Johnson talc subsidiary's bid to revive its trade libel claim over a scientific article linking asbestos in talc to mesothelioma.
-
January 06, 2026
Public Health Atty Talks Botulism, Infants And FDA Staffing
Three years ago, a bacterial outbreak at a Michigan manufacturing plant sparked a shutdown and a national infant formula shortage. Another episode last year at a formula plant in Iowa should be a red flag for the public and a short-handed FDA, according to Sarah Sorscher of the Center for Science in the Public Interest.
-
January 06, 2026
Drugmakers Fight Multifront Legal Battles Over GLP-1s
In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitors, alleged counterfeits and telehealth providers.
-
January 06, 2026
Wyo. High Court Strikes Down 2 Laws Restricting Abortion
The Wyoming Supreme Court struck down the state's near-total abortion ban and a first-of-its-kind prohibition on abortion pills on Tuesday, saying the laws violated the state constitution.
-
January 06, 2026
Ill. Judge Trims Most Of Walgreens Shareholder Suit
An Illinois federal judge on Monday dismissed most claims in a lawsuit alleging Walgreens inflated share prices by concealing the lack of viability of its pharmacy division and primary care investment, warning shareholders not to "waste judicial resources" in amending their allegations by claiming straightforward statements are misleading "absent a coherent argument as to why."
-
January 06, 2026
Healthcare Litigator Moves Practice To Troutman In Philly
A litigator specializing in healthcare and product liability cases has joined Troutman Pepper Locke LLP's Philadelphia office after practicing for more than six years with Campbell Conroy & O'Neil PC.
-
January 06, 2026
Federal Prosecutor Rejoins King & Spalding In Atlanta
A former federal prosecutor who left King & Spalding LLP five years ago for an assistant U.S. attorney role has returned to the firm as an Atlanta-based partner in its product liability and mass torts practice, according to a Tuesday announcement.
Expert Analysis
-
What Ethics Rules Say On Atty Discipline For Online Speech
Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.
-
Junior Attys Must Beware Of 5 Common Legal Brief Mistakes
Excerpt from Practical Guidance
Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.
-
Opinion
State AGs, Not Local Officials, Should Lead Public Litigation
Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.
-
3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue
A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.
-
Texas Suit Marks Renewed Focus On Service Kickback Theory
After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.
-
Series
Power To The Paralegals: How And Why Training Must Evolve
Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.
-
Series
Playing Softball Makes Me A Better Lawyer
My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.
-
5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting
As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.
-
Fed. Circ. In August: A Framework For AIA Derivation Disputes
In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.
-
USPTO's Track One A Reliable Patent Pathway Amid Backlog
As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.
-
Vanda Ruling Opens Door For Contesting FDA Drug Denials
The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.
-
Series
Law School's Missed Lessons: Mastering Time Management
Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.
-
Pharma Copay Programs Raise Complex Economic Questions
The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.